throbber
P-00133497
`
`
`
`Production of the Basic Fibroblast Growth Factor
`
`(bFGF) in a High Cell Density Process by means of
`
`Recombinant Escherichia coli
`
`
`
`From the Department of Mechanical Engineering and Electrical Engineering
`
`of the Technical University Carolo-Wilhelmina
`
`in Braunschweig
`
`
`
`Approved
`
`Doctor of Engineering
`
`(Dr.-Ing.)
`
`Dissertation
`
`
`
`by
`
`Dipl.-Ing. Anke Seeger
`
`of Rathenow
`
`
`
`
`
`BEQ 1020
`Page 1
`
`

`
`Production of the Basic Fibroblast Growth Factor
`
`(bFGF) in a High Cell Density Process by means of
`
`Recombinant Escherichia coli
`
`
`
`From the Department of Mechanical Engineering and Electrical Engineering
`
`of the Technical University Carolo-Wilhelmina
`
`in Braunschweig
`
`
`
`Approved
`
`Doctor of Engineering
`
`(Dr.-Ing.)
`
`Dissertation
`
`
`
`by
`
`Dipl.-Ing. Anke Seeger
`
`of Rathenow
`
`
`
`
`
`BEQ 1020
`Page 2
`
`

`
`
`
`
`
`1st Referee
`2nd Referee
`Submitted on:
`Oral Examination:
`
`
`Prof. Dr. D. C. Hempel
`Prof. Dr. W.-D. Deckwer
`05/31/1995
`08/30/1995
`
`1995
`
`
`
`
`
`BEQ 1020
`Page 3
`
`

`
`The present work was produced during the period from April, 1992 to April, 1995 at the
`
`Gesellschaft für Biotechnologische Forschung mbH [Society for Biotechnological Research
`
`mbH], Braunschweig, under the direction of Prof. Dr. W.-D. Deckwer, whom I thank for
`
`suggesting the thesis and supporting my work.
`
`
`
`Furthermore, I would like to thank Prof. Dr. D. C. Hempel for conducting the review.
`
` A
`
` special thanks goes to Dr. U. Rinas, who helped me familiarize myself with this subject
`
`matter, and provided supervision during this study. She provided a great deal of help through her
`
`willingness to engage in discussion, in resolving problems that arose, or preventing them from
`
`occurring.
`
`
`
`Furthermore, I would like to thank all of my co-workers in the study group for developing
`
`methods, for the pleasant work climate and for their assistance. I would like to thank Mrs. M.
`
`Schreiner for her excellent technical assistance.
`
`
`
`Pero vull també agrair molt especialment a en David per la seva ajuda i comprensió mostrada
`
`durant la meva promoció.
`
` I
`
` would like to thank my family with all my heart for the support they have provided me during
`
`my education, without whom I could never have completed this study.
`
`BEQ 1020
`Page 4
`
`

`
`Table of Contents
`
`
`
`I
`
`
`
`1.
`
`
`
`
`
`
`
`Introduction ............................................................................................................1
`
`1.1
`
`1.2
`
`Introduction and Overview of References ..................................................1
`
`Presentation .................................................................................................6
`
`2.
`
`Theoretical Background ........................................................................................7
`
`2.1
`
`2.2
`
`2.3
`
`
`
`
`
`
`
`Basic Fibroblast Growth Factor (bFGF) .....................................................7
`
`Cultivation of Escherichia coli in a High Cell Density Process ..................9
`
`Intracellular Reactions to Stress Situations ...............................................11
`
`2.3.1
`
`Influence of Temperature on Growth ...........................................11
`
`2.3.2
`
`Influence of Temperature on Protein Synthesis ............................11
`
`2.3.3 Degradation of RNA Components in Reaction to Stress ..............13
`
`2.4
`
`Folding of Recombinant Proteins .............................................................17
`
`
`
`
`
`2.4.1 Molecular Mechanisms .................................................................17
`
`2.4.2 Kinetics of Protein Folding ...........................................................18
`
`2.5
`
`Purification of Basic Fibroblast Growth Factors ......................................20
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3.
`
`Materials and Methods .......................................................................................22
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3.1
`
`Production of bFGF ..................................................................................22
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3.2
`
`3.3
`
`
`
`3.1.1 Microorganisms and Plasmids ......................................................22
`
`3.1.2 Stock Culture ................................................................................23
`
`3.1.3 Cultivation Media .........................................................................23
`
`
`
`
`
`3.1.3.1 LB-Medium ....................................................................23
`
`3.1.3.2 Media for High Cell Density Cultivation .......................24
`
`3.1.4 Preparatory Cultures .....................................................................25
`
`3.1.5 Experiment Set-up and Comparison of Reactor Types Used .......25
`
`3.1.6 Course of the High Cell Density Cultivation for
`
`Production of bFGF ......................................................................28
`
`On-line Analysis during High Cell Density Cultivation ...........................31
`
`Off-line Analysis during High Cell Density Cultivation ..........................33
`
`3.3.1 Determination of Cell Growth ......................................................33
`
`
`
`BEQ 1020
`Page 5
`
`

`
`Table of Contents
`
`
`
`
`
`II
`
`
`
`
`
`3.3.2 Determination of Glucose, Ammonia and Phosphate Ions ...........33
`
`3.3.3 Determination of Osmotic Strength ..............................................34
`
`3.4
`
`Determination of Metabolism By-products through
`
`High-Performance Liquid Chromatography (HPLC) ...............................35
`
`Quantitative bFGF determination .............................................................37
`
`Qualitative Protein Analysis .....................................................................38
`
`3.6.1 Goal, Sample Preparation, and Chemicals Used ..........................38
`
`3.6.2 Gradient Gels ................................................................................39
`
`3.6.3 2-D Gel Electrophoresis for Isolating bFGF .................................42
`
`3.6.4 Transference of Proteins to 1-D or 2-D gels
`
`to Membranes by Means of Blotting for Antibody-Specific
`
`Dying 44
`
`3.6.5 Antibody Dying ............................................................................44
`
`3.5
`
`3.6
`
`
`
`
`
`
`
`
`
`
`
`3.7
`
`Regeneration Strategy for bFGF ...............................................................45
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3.7.1 Cell Harvest ..................................................................................45
`
`3.7.2 Cell Degradation ...........................................................................45
`
`3.7.3 Separation of the Insoluble Protein Fractions from the
`
`Soluble Proteins ............................................................................46
`
`3.7.4
`
`Ion Exchange Chromatography ....................................................46
`
`3.7.5 Dialysis .........................................................................................47
`
`3.7.6 Heparin Affinity Chromatography ................................................48
`
`3.7.7 Recording of Adsorption Isotherms for bFGF
`
`on CM-sepharose and Heparin ......................................................48
`
`3.8 Measurement of the Circular Dichroism (CD Spectra) .............................49
`
`3.9
`
`Sequence Analysis ....................................................................................50
`
`3.10 Biological Activity Test for bFGF ............................................................51
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4.
`
`Results and Discussion ........................................................................................52
`
`
`
`
`
`
`
`
`
`4.1
`
`Examination of the Plasmids Used with Regard to
`
`their Expression Behavior .........................................................................52
`
`4.1.1 Shaking Flask Test ........................................................................52
`
`4.1.2 Comparison of the Expression System in
`
`
`
`
`
`High Cell Density Cultivations .....................................................54
`
`
`
`BEQ 1020
`Page 6
`
`

`
`Table of Contents
`
`
`
`
`
`III
`
`4.2
`
`Production of bFGF by Means of Thermal Induction ..............................61
`
`
`
`
`
`
`
`
`
`4.2.1
`
`Influence of the Induction Point in Time ......................................61
`
`4.2.2 Kinetic Considerations ...................................................................68
`
`
`
`
`
`4.2.2.1 Depiction of the Expression Rate ..................................68
`
`4.2.2.2 Depiction of the in vivo Folding and
`
`4.3
`
`Production of bFGF in 50 l Measures .......................................................80
`
`Stability of bFGF ............................................................73
`
`4.4 Metabolism Examinations of E. coli During
`
`High Cell Density Cultivations .................................................................84
`
`4.4.1 Enrichment of Metabolism By-Products in the Medium ..............84
`
`4.4.2 Enrichment of Uracil in the Medium ............................................88
`
`4.4.3
`
`Influence of Osmotic strength of the Medium ..............................93
`
`Results of Discussion of the Chromatographic Purification Steps ...........95
`
`Product Characterization .........................................................................106
`
`4.6.1 2-D Gel Electrophoresis ..............................................................106
`
`4.6.2 Measurement of the Circular Dichroism (CD) of bFGF .............109
`
`4.6.3 Sequence Analysis of the Recombinant Proteins bFGF ..............112
`
`4.6.4 Biological Activity Test for bFGF ..............................................114
`
`
`
`
`
`
`
`4.5
`
`4.6
`
`
`
`
`
`
`
`
`
`Summary ............................................................................................................117
`
`Symbol Index .....................................................................................................120
`
`6.1
`
`6.2
`
`Abbreviations ..........................................................................................120
`
`Formula Symbols ....................................................................................121
`
`Bibliography ......................................................................................................123
`
`Appendix ............................................................................................................133
`
`8.1
`
`8.2
`
`High Cell Density Cultivations ...............................................................133
`
`Batch Tests for Bonding bFGF to CM-sepharose and Heparin ..............150
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5.
`
`
`
`6.
`
`
`
`
`
`
`
`7.
`
`
`
`8.
`
`
`
`
`
`
`
`BEQ 1020
`Page 7
`
`

`
`1. Introduction and Goal
`
`
`
`1.1
`
`Introduction and Overview of References
`
`
`
`As a result of the strong dissemination of the genetic engineering methods for targeted
`
`modification of nucleic acid sequences of proteins, so-called “genetic engineering” has become a
`
`primary tool in bioengineering in recent years. The production of commercially interesting
`
`proteins is of primary interest thereby, wherein, by means of the production of these substances,
`
`new perspectives have also been quite frequently explored in the medical field thereby. A few
`
`examples of commercially important proteins produced in genetically modified microorganisms
`
`are listed below (Georgiou, 1988).
`
`
`
`Hormones:
`
`Enzymes:
`
`Growth hormones, endorphin, insulin, Factor VIII
`
`Protease, cellulase, pullulanase, prochymosin, elastase, urokinase,
`
`streptokinase, superoxide dismutase
`
`Phys. active substances:
`
`Interferons, interleukins, tumor necrosis factor
`
`Inoculants:
`
`Hepatitis B surface antigen
`
` A
`
` market for 1995 in the USA of 2,400 million dollars was predicted thereby, just for the group
`
`of growth hormones (Robinson et al., 1992). It is therefore not surprising that the production of
`
`these proteins in recombinant microorganisms was preferred over the comparably difficult
`
`isolation thereof from the tissues in which they originate, which produces a lower yield
`
`(Gospodarowicz et al., 1985; Gospodarowicz et al., 1978).
`
`
`
`In the framework of planning a process for the production of recombinant proteins, in general,
`
`the selection of suitable host organisms, an induction system, and a process strategy had to be
`
`taken into account. The selection of a suitable host strain from the numerous known
`
`microorganisms was strongly limited by the quantity of available biological data regarding a
`
`strain. For this reason, the well researched Gram-negative bacteria Escherichia coli remains the
`
`BEQ 1020
`Page 8
`
`

`
`favorite when selecting an easily cultivated host organism. Likewise widely disseminated and
`
`used specifically for the production of enzymes is the strain Bacillus sp. (Georgiou, 1988).
`
`
`
`For commercial production of a recombinant protein with a high yield in recombinant E. coli
`
`strains, it is furthermore necessary to combine an effective induction system with a high cell
`
`density process, and to ensure a high degree of stability of the recombinant protein through the
`
`selection of a suitable cultivation parameter. The various induction systems have thus been the
`
`subject of numerous studies in recent years. A good summary of induction systems frequently
`
`used in E. coli is provided in the publication by Georgiou (1988).
`
`
`
`As a prerequisite for a cultivation of E. coli to a high cell density of up to 148 g/l, a fed-batch
`
`method has been developed at the GBF, which is based on a carbon limitation of the cells during
`
`the fed-batch phase (Korz et al., 1994; Korz, 1992). The constant growth rate reduced in this
`
`manner prevents an oxygen limitation and an enrichment of by-products that have a detrimental
`
`effect on metabolism. Numerous pharmaceutically important proteins have already been
`
`produced in cultivations with relatively high cell densities. Some of these are listed in Table 1.
`
`
`
`Such a process for a high cell density cultivation with the synthesis of foreign proteins
`
`furthermore offers the possibility of examining the host organism in stress situations, such as
`
`higher temperatures, or carbon deficits, with respect to its metabolism. As a result, conclusions
`
`can be drawn regarding the fundamental microbial processes in bacteria, which in part can be
`
`generalized for other organisms. As a result, to date the questions regarding the purpose and
`
`effects of the production of additional proteins induced in E. coli at higher temperatures, the so-
`
`called heat shock proteins, have not been fully resolved; a phenomenon that extends from the
`
`bacteria to human organisms. Due to the very high cell densities during the cultivation,
`
`measurable parameters, which indicate a change in metabolism, e.g. increased heat generation,
`
`BEQ 1020
`Page 9
`
`

`
`release of proteins or metabolism by-products, are increased, and thus made more quickly
`
`available (possibly on-line).
`
`
`
`
`
`Product
`
`Max. Product
`Concentration
`Interleukin-2
`
`1.02 g/l
`Interleukin-2
`
`40 mg/gBTM
`Human Epidermal Growth
`Factor
`
`60 mg/l
`Interferon-Alpha1
`
`2x7 107U/gBTM
`Interferon-Alpha1
`
`55x107U/gBTM
`bFGF
`
`23.2 mg/l
`
`Malaria antigen
`
`12 mg/g
`
`Strain
`
`Plasmid
`
`Promoter
`
`Induction system
`
`M5248
`
`pNKM21
`HW21-2
`
`pFC54
`HB 101
`
`pTRLBT1
`
`BMH7118
`
`PBV-867
`TG1
`
`pBB210
`MH294
`
`pTB669
`
`AR58
`
`pR32tet32
`
`PL
`
`30° C to 42° C
`PL
`
`30° C to 37° C
`Ptrp
`
`Removal of Tryptophan from
`the medium
`PL
`
`30° C to 37° C
`constitutive
`
`Ptrp
`
`Addition of 3--indoleacrylic
`acid
`PL
`
`30° C to 42° C
`
`Process
`
`Max. BTM
`
`DO-stat
`
`29 g/l
`Fed-batch
`
`42 g/l
`Fed-batch
`
`21 g/l
`
`Fed-batch
`
`50-80 g/l
`Fed-batch
`
`60 g/l
`Batch
`
`no
`information
`Fed-batch
`
`50 g/l
`
`Reference
`
`Seo et al.
`(1992)
`
`Macdonnald et al.
`(1990)
`
`Shimizu et al.
`(1990)
`
`Yang et al.
`(1992)
`
`Riesenberg et al.
`(1990)
`
`Iwane et al.
`(1987)
`
`Zabriskie et al.
`(1987)
`
`Table 1.1: Pharmaceutically important proteins, produced in recombinant E. coli strains.
`
`
`
`With the production of pharmaceutically important proteins, one main problem thereby is the
`
`purification of proteins in their native forms. Many of the recombinant proteins are preferably
`
`deposited in their insoluble form, the so-called inclusion bodies, in the cells (Schein, 1989;
`
`BEQ 1020
`Page 10
`
`

`
`Shimizu et al., 1991). These are normally biologically inactive, and require extensive cleansing,
`
`denaturing and renaturation steps (Bernardez-Clark et al., 1991).
`
`
`
`The frequently occurring proteolytic degradation in the cells may also be another obstacle in the
`
`production of recombinant proteins. As such, Talmadge et el. (1982) has shown that the half-life
`
`period of the pharmaceutically important protein preproinsulin, a preliminary stage of insulin, is
`
`less than two minutes in cytoplasm of E. coli. Some recombinant proteins are recognized as
`
`abnormal and degraded by the cells – in comparison with the native proteins – wherein this is
`
`clearly not observed with all recombinant proteins, and appears to be dependent on the sequence
`
`of its first amino acids (Georgiou, 1988).
`
`
`
`The regeneration of recombinant produced proteins is also problematic, because important
`
`environmental parameters, such as the pH value and the temperature, can only be varied within
`
`narrow ranges, because this would otherwise lead to an aggregation of the protein molecules.
`
`Furthermore, the use of organic solvents may lead to a denaturing of the proteins.
`
` A
`
` major problem is quality control for the recombinant proteins. In order to ensure that the use
`
`thereof does not present a risk in human medicine, all of the possible contaminants must be
`
`eliminated. Contaminants may have a directly damaging effect on test subjects thereby, or they
`
`may have a detrimental effect on the effect of the therapeutic agent that is being administered.
`
`Frequently occurring contaminants having negative effects are, e.g. oncogene DNA, endotoxins,
`
`infectious agents or materials that give rise to an immune reaction (Anicetti et al., 1989). The
`
`protein itself can also be a starting point for contaminants as a result of undesired
`
`heterogeneities, e.g. deamidation or amino acid substitution (Manning et al., 1989; Liu, 1992). A
`
`few typical contaminants, frequently found in pharmaceutical proteins, are listed in the following
`
`Table, according to the corresponding detection methods.
`
`
`
`
`
`BEQ 1020
`Page 11
`
`

`
`
`Contaminant
`
`Endotoxins
`
`
`Cell or media proteins
`
`
`Infectious agents
`
`Product variants:
`deamidation products
`oxidation products
`amino acid substitutions
`aggregated forms
`proteolytic products
`
`
`
`
`Detection method
`
`LAL1, rabbit pyrogen
`
`
`SDS-Page2, Immune test
`
`
`Reverse transcriptase test
`Cell cultures; cytopathic effects, electron microscope
`
`
`SDS-Page2, isoelectric focusing
`HPLC
`Edman degradation analysis
`SDS-Page2
`SDS-Page2, HPLC
`
`
`Table 1.2: Frequently occurring contaminants in pharmaceutical proteins and the corresponding
`
`detection methods (Anicetti et al., 1989), LAL1 limulus amebocyte lysate, SDS-Page2 Sodium
`
`dodecyl sulfate polyacrylamide gel electrophoresis
`
`
`
`These types of contaminants in the protein solution are problematic because they are difficult to
`
`detect, and can only be detected by means of respective very specific analytical methods. Of
`
`course, this does not only apply to proteins that are produced through genetic engineering
`
`approaches, but rather for pharmaceutical products that are isolated directly from the initial
`
`tissues as well. As a consequence, this has resulted in the past in infections of personnel and
`
`patients through undetected viral contaminants, e.g. AIDS or Ebola. For this reason, it is very
`
`important that the information regarding the purity of a protein must always be regarded in
`
`conjunction with the analytical methods that are used, the sensitivity thereof regarding specific
`
`heterogeneities, and the reliability thereof.
`
`
`
`
`
`BEQ 1020
`Page 12
`
`

`
`1.2 Presentation
`
`
`
`The goal of this work was the development of an economically reasonable process for the
`
`production of the basic fibroblast growth factor (bFGF) as a protein of pharmaceutical interest
`
`using a recombinant Escherichia coli strain. The high cell density process developed at the GBF
`
`could be used for this (Korz, 1992). As an induction system, a temperature inducible system was
`
`to be compared with a chemically inducible system. Both systems were to be compared with
`
`regard to their influence on the cell growth, the product yield and the solubility – and thus to the
`
`biological activity – of the synthesized pharmaceutical protein.
`
`
`
`In the case of a deposit of the recombinant protein in insoluble inclusion bodies, it would be
`
`desirable to characterize method and biological effect variables, and to optimize the process in
`
`favor of the soluble bFGF fractions.
`
`
`
`Furthermore, the high cell density cultivation is to be used for examining the metabolism of the
`
`host organism with regard to its behavior in stress situations, e.g. glucose deficit, or high
`
`temperatures.
`
`
`
`Another primary focus is the purification of the soluble fraction of the target protein. For this, a
`
`gentle product purification is sought for obtaining a high recovery rate in as few purification
`
`steps as possible.
`
`
`
`Lastly, the purified protein is to be examined with regard to potentially arising contaminants,
`
`structural changes or micro-heterogeneities.
`
`
`
`BEQ 1020
`Page 13
`
`

`
`2. Theoretical Background
`
`
`
`2.1 The Basic Fibroblast Groth Factor (bFGF)
`
`
`
`The basic fibroblast growth factor (bFGF) belongs to a class of growth hormones that can be
`
`subdivided into six different factors, each of which has a different medical application potential.
`
`The most common terminology for these most important growth factors are: epidermal growth
`
`factor (EGF), fibroblast growth factor (FGF), transforming growth factor  (TGF-),
`
`transforming growth factor  (TGF-), insulin-like growth factor (IGF), and platelet-derived
`
`growth factor (PDGF) (Robinson et al., 1992).
`
`
`The basic fibroblast growth factor (bFGF) is a single strain, non-glycosylated polypeptide, which
`
`was originally isolated from cattle brain and the bovine pituitary gland (Gospodarowicz, 1974).
`
`It was also found in numerous tissues and organs, such as human brain and placenta, cattle retina
`
`and kidney, the hypothalamus, thymus, amygdala, and various types of tumors (Gospodarowicz,
`
`1987). Due to the isolation of bFGF in numerous tissues and organs, it is described in the
`
`relevant literature under various synonyms, such as endothelial growth factor, tumor angionesis
`
`factor or hepatoma growth factor. The characterizing property of bFGF is its isoelectric point,
`
`which lies at 9.6 (Gospodarowicz, 1987).
`
`
`The amino acid sequences of bovine and human bFGF are known and exhibit a 98.7% homology
`
`(Abraham et al., 1986). The molecular weight of the 155 amino acid forms of the bFGF is 18
`
`kDa. The existence of numerous bFGF forms could be demonstrated in the various initial
`
`tissues, which differ in terms of their numbers of amino acids and molecular weights. Thus, in
`
`addition to the original 146 and 155 amino acid forms isolated in cattle brain and pituitary gland
`
`having a molecular weight of 16.5 and 18 kDa, a 157 amino acid form of the bFGF was found in
`
`the placenta, and a 163 amino acid form of bFGF was found in hepatoma cells (Brigstock et al.,
`
`1990). Sequencing has shown that these are not N-terminus extensions, which cannot be
`
`BEQ 1020
`Page 14
`
`

`
`explained through post-translational modifications. It is assumed that the longer bFGF forms are
`
`encoded with the same cDNA, but are initiated by the CUG codon that is an alternative to the
`
`AUG codon (Prats et al., 1989; Brigstock et al., 1990). So far, however, it has not been possible
`
`to find any indication of the function of the N-terminus extensions; the various bFGF forms do
`
`not differ in terms of their biological activity (Brigstock et al., 1990).
`
`
`The protein contains 4 cysteines, which, however, are not capable of forming disulfide bridges,
`
`due to their spatial arrangement. Examinations of three-dimensional structures of bFGF have
`
`furthermore shown that its topology has a strong homology to that of the interleukin 1, and
`
`consists mainly of -sheet structures (Erikson et al., 1991; Zhang et al., 1991).
`
`
`
`
`
`
`
`Fig. 2.1: The structure of the basic fibroblast growth factor. This is the bFGF form according to
`
`Erikson et al. (1991) consisting of 146 amino acids, recorded using the computer program
`
`BRAGI/GBF. The dark grey markings indicated -sheet structures, the black markings indicate
`
`the accordingly labeled cysteine side chains.
`
`
`
`
`
`BEQ 1020
`Page 15
`
`

`
`bFGF is a mitogen for endothelial cells as well as a large number of cells originating in the
`
`mesodermal and neural-ectodermal regions (Gospodarowicz, 1987; Gospodarowicz et al., 1987).
`
`In addition, it induces the differentiation of nerve cells and prevents the de-differentiation of
`
`vascular and corneal endothelial cells. bFGF is an angiogenetic factor, i.e. it stimulates the
`
`formation of blood vessels (Gospodarowicz et al., 1979; Togari et al., 1987). The molecular
`
`mechanism is based on the tyrosine-specific protein kinase activity of the bFGF receptor, which
`
`can catalyze the phosphorylation of a cellular substrate protein. So far, three bFGF receptors
`
`have been identified (Bradshaw et al., 1987). Baird et al. (1988) was able to show that the
`
`peptide fragments 24-68 and 106-115 bond with the bFGF receptors, of which 103-104 per cell
`
`have been found.
`
` A
`
` broad application spectrum, in particular in the field of medicine, is obtained from the various
`
`functions of bFGF. By stimulating fibroblasts, it causes an accelerated healing process for
`
`wounds, which is of particular interest with regard to chronic or poorly healing wounds. In the
`
`treatment of thrombosis, bFGF can induce a blood vessel regeneration, and thus offers new
`
`possibilities for the treatment thereof (Buntrock et al., 1982; Buntrock et al., 1984). Further
`
`clinical fields of application arise in tissue transplants and through the possibility of nerve cell
`
`regeneration. It is to be expected that the demand for growth factors will increase sharply in the
`
`future, due to the many various application possibilities (Prats et al., 1989).
`
`
`
`2.2 Cultivation of Escherichia coli in a High Cell Density Process
`
`
`
`The two-phase method developed at the GBF for cultivating the Gram-negative bacteria
`
`Escherichia coli up to a cell density of 148 g/l is based on a fed-batch strategy, in which a
`
`controlled feeding of the carbon source follows the batch phase. In order to prevent a substrate
`
`enrichment in the medium, and to ensure a growth having a constant growth rate, the feeding
`
`occurs with a defined, exponentially increasing speed (Korz, 1992; Korz et al., 1994). In
`
`BEQ 1020
`Page 16
`
`

`
`contrast to this simple method for maintaining a constant growth rate by means of a pre-
`
`calculated substrate mass flow, a complex regulating strategy has been proposed by Riesenberg
`
`et al. (1991). With this, the current growth rate of the culture can be continuously calculated
`
`from the data provided by the discharge gas analysis, and controlled via the speed of the stirrer.
`
`A second control loop guarantees the pO2 control through variation of the glucose feed.
`
` A
`
` prerequisite for the development of this process was the observations of the Pasteur and
`
`Crabtree effects in the bacterial metabolism of E. coli (Weide et al., 1979). Oxygen played an
`
`important role thereby as an end acceptor for electrons of the respiratory chain in the metabolism
`
`of the facultative anaerobic microorganism. The fact that, with an oxygen deficit caused by
`
`shortening the electron transport chain, this leads to a reduction of the ATP production and thus
`
`to a reduced biomass formation, emphasizes the necessity of a sufficient oxygen supply for the
`
`cells in a high cell density cultivation. By inhibiting the pyruvate dehydrogenase complex,
`
`pyruvate is reduced via acetyl-CoA, under anaerobic conditions, to acetate, a metabolism by-
`
`product that has an inhibiting effect on both growth as well as product formation (Pasteur effect).
`
`A defined growth rate ensures a controllable oxygen consumption of the cells thereby, and thus
`
`enables growth without oxygen limitation.
`
`
`
`The bacterial Crabtree effect relates to the interaction between glucose concentrations in media,
`
`and the glucose metabolism under aerobic conditions. Thus, a high concentration of glucose in
`
`the medium results in a repression of the formation of certain enzymes of the TCA cycle, and in
`
`particular, the NADH dehydrogenase and the succinate dehydrogenase are inhibited, which in
`
`turn leads to a greater enrichment of inhibiting metabolism by-products such as acetate
`
`(Hollywood et al., 1976).
`
`
`
`
`
`BEQ 1020
`Page 17
`
`

`
`2.3 Intracellular Reactions to Stress Situations
`
`
`
`2.3.1
`
`Influence of Temperature on Growth
`
`
`
`Increasing the cultivation temperature causes stress in the metabolism of the mesophilic
`
`organism E. coli. In the temperature range of 20°-37° C, the so-called normal or Arrhenius
`
`range, the growth rate represents a simple function of the temperature. With temperature
`
`fluctuations within this range, the growth rate that is characteristic of the current temperature is
`
`adjusted to without delay.
`
`
`
`With temperatures higher than 40° C, in contrast, the growth rate speed decreases until it reaches
`
`a full stop in growth in relation to the medium. It has been concluded from these observations
`
`that the effects of temperature fluctuations in the normal range can be compensated for through
`
`an adjustment of the enzyme activity, while at higher temperatures, changes in individual cell
`
`components, such as in the protein, fatty acids and phospholipid composition could be observed
`
`(Neidhardt et al., 1987).
`
`
`
`2.3.2
`
`Influence of Temperature on Protein Synthesis
`
`
`
`While proteins, which are involved in the transcription or the translation, occur at temperatures
`
`above 40° C in E. coli in a reduced quantity in the cells, a group of at least 17 polypeptides has
`
`been identified, the expression of which can be induced more strongly by a factor of up to 100
`
`when the temperature is increased (Reeve et al., 1984; Lemaux et al., 1978; Yamamori et al.,
`
`1982). A selection of the most important heat shock proteins identified so far is listed in the
`
`
`
`following Table.
`
`
`
`BEQ 1020
`Page 18
`
`

`
`Function
`
`Gene MG
`(kDa)
`
`25.300
`
`grpE
`
`Initiation of the DNA replication
`
`mopA 62.833 Stabilizing, complex forming in the protein folding, is necessary for 1-phage
`head assembly
`
`69.121 has 5’-nucleotidase and weak ATP-ase activity, is capable of auto-
`phosphorylation
`
`70.263 Sub-unit of the RNA polymerase, responsible for normal promoter detection,
`regulates the synthesis of other heat shock proteins
`
`mopB 10.670 Proteolysis, forms complex with GroEL, inhibits its ATP-ase activity
`
`60.500 participates in the formation of adenylated nucleotides.
`
`dnaK
`
`rpoD
`
`lysU
`
`Protein
`name
`
`GrpE
`
`GroEL
`
`DnaK
`
`Sigma
`
`GroES
`
`Lysyl-
`tRNA
`synthetase
`Form 2
`
`
`
`Table 2.1: List of selected heat shock protein of E. coli (Martin et al., 1991; DeBernardez-Clark
`
`et al., 1991; Niedhardt et al., 1987; Varshavsky, 1983)
`
`
`
`These so-called heat shock proteins (HSP) result in not only an improved heat tolerance of the
`
`cell, they are also identical in part to proteins induced through oxidative stress and the addition
`
`of ethanol. Their role in the survival mechanism of E. coli is a theme discussed at length in
`
`technical literature. VanBogelen et al. (1987) was able to demonstrate, through induction of the
`
`BEQ 1020
`Page 19
`
`

`
`regulons for SOS, heat shock and oxidative stress, that these stress regulons were induced
`
`independently of one another, wherein some stress factors, e.g. CdCl2, induce numerous
`
`regulons. A decisive function of these proteins induced through heat is, intracellularly, their
`
`influence on the correct folding of proteins.
`
`
`
`In numerous processes for the production of proteins, large quantit

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket